Non-Hodgkin lymphoma is a malignant tumor of the blood system formed by malignant clonal proliferation of lymphoid organs or lymphoid tissues. It is a heterogeneous disease that seriously threatens human health. The incidence of this disease is increasing worldwide, and it can be divided into two types: B-lymphocyte-derived and T-lymphocyte-derived (T-NHL) according to immune typing. Among them, T-NHL is a highly malignant clonal disease. The disease of T-NHL patients often progresses rapidly, with poor long-term efficacy and poor prognosis. Therefore, it is necessary to search for some abnormally expressed protein molecules in T-NHL cells and conduct functional studies at the molecular level to promote the development of clinical target drugs and gene drugs.

Target Genes Delivered In Vivo in Non-Hodgkin Lymphoma T Cell

Figure 1. Altered gene expression and mutations associated with key metabolic pathways found in B-NHL subtypes. (Abdullah Alfaifi, et al.; 2023)

The development of gene-targeted therapeutic drugs is an important direction for future cancer treatment research and development. Only by screening disease-related genes and understanding their functions and their roles in the occurrence and development of diseases can we develop corresponding drugs. These drugs can directly condition the gene expression in the target cells to achieve the purpose of treatment. For example, antisense drugs can reduce the expression of certain genes that are abnormally expressed in tumors to achieve the purpose of tumor control. Comparative analysis of lymphoma and normal tissues by bioinformatic methods revealed that functional proteins commonly abnormally expressed in lymphoma biology include (1) genetic alterations that promote growth and survival (eg, CDKN2A mutations that alter cell cycle control, affect JAK- (2) constitutive upregulation of key signaling pathways (eg, those involving CD79B, MYD88, CARD11); (3) inhibition of apoptosis (eg, upregulation of BCL2 via translocation or copy number gain) (4) blocked terminal differentiation (eg, BCL6 translocation and PRDM1 loss); (5) immune escape (eg, PDL1 translocation, and mutations involving CD58 or B2M); (6) associated with chromatin remodeling and tissue Global alteration of genes involved in protein modification (eg, mutations involving EZH2, CREBBP, EP300, KMT2D).

In addition to the above genes, there are interesting non-hodgkin lymphoma T cell -related genes that need to be explored and studied. Therefore, there is a need for an in vivo transfection system that can precisely target non-hodgkin lymphoma T cell tissue and be taken up by tumor cells to function in vivo. The system can help researchers overcome various challenges encountered during in vivo transfection:

• Relevant molecular function studies can only be carried out in vitro, lacking important in vivo data
• Using in vitro transfection system for in vivo transfection, the transfection efficiency is very low;
• The in vivo transfection system used is not specific to non-hodgkin lymphoma T cell tissues and cells, and is toxic to the body;
• The in vivo transfection system used cannot penetrate the non-hodgkin lymphoma T cell tissue into the tumor tissue;
• The nucleic acid load of the in vivo transfection system is low, and it is difficult to achieve the expected effect;
• Etc…

Our Advantage:

• We can provide an in vivo transfection system for non-hodgkin lymphoma T cell tissues and cells to achieve efficient transfection
• Our system can target multiple targets at the same time, improving targeting accuracy
• The in vivo transfection system has low toxicity to the body and is safe to use
• In vivo transfection system vectors can protect nucleic acids from degradation during in vivo delivery
• Persistent knockout effect in experimental animals after a single injection
• The system load is high, and the transfection needs of different doses can be completed
• Professional design and service team to provide you with reliable service and technical support
• Timely feedback of technical reports

CD BioSciences specializes in developing transfection systems and customizing transfection reagents for gene transfection using our core technologies. With our high-quality products and services, your transfection results can be greatly improved. If you can't find a perfect in vivo transfection system, you can contact us. We can provide one-to-one personal customization service.

References

1. Mujahid A.Rizvi, et al.; T-cell non-Hodgkin lymphoma. Blood. 2006, 107(4), Pages 1255-1264.
2. Ryan, et al.; Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma. Hematology/Oncology Clinics of North America. 2019, 33(4), 553–574.
3. Shankland KR, et al.; Non-Hodgkin lymphoma. Lancet. 2012; 380: 848-875
4. Abdullah Alfaifi, et al.; Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin's Lymphoma. Diagnostics. 2023, 13(5), 861.

* For research use only. Not for use in clinical diagnosis or treatment of humans or animals.